Evidence map›Paper›PMID 24399558›Full record

ArticleJAMA2014

Pharmacological treatments for smoking cessation.

Kate Cahill, Sarah Stevens, Tim Lancaster

Abstract readComment
PubMed Publisher
In one paragraph

Article in JAMA, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

86 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Changes in Nicotine Dependence Among Smokers Using Electronic Cigarettes to Reduce Cigarette Smoking in a Randomized Controlled Trial.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2023
    Trial
  10. Evaluating Treatment Mechanisms of Varenicline: Mediation by Affect and Craving.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2022
    Trial
  11. Trial
  12. Trial
  13. IQOSInternational journal of environmental research and public health · 2018
    Trial
  14. Brief Web-Based Interventions for Young Adult Smokers With Severe Mental Illnesses: A Randomized, Controlled Pilot Study.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2018
    Trial
  15. Trial
  16. Trial
  17. Trial
  18. Step Care treatment for smoking cessation.Health education research · 2017
    Trial
  19. Long-term follow-up of psilocybin-facilitated smoking cessation.The American journal of drug and alcohol abuse · 2017
    Trial
  20. Trial

26 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Kate CahillDepartment of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom2Cochrane Tobacco Addiction Group, University of Oxford, Oxford, United Kingdom.
Sarah StevensDepartment of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.
Tim LancasterDepartment of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom2Cochrane Tobacco Addiction Group, University of Oxford, Oxford, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

clinical questionAmong the 3 first-line smoking cessation treatments (nicotine replacement therapy [NRT], bupropion, and varenicline), which is most effective in helping people who smoke achieve and maintain abstinence from smoking for at least 6 months, and what serious adverse events are associated with each? BOTTOM LINE: Higher rates of smoking cessation were associated with NRT (17.6%) and bupropion (19.1%) compared with placebo (10.6%). Varenicline (27.6%) and combination NRT (31.5%) (eg, patch plus inhaler) were most effective for achieving smoking cessation. None of the therapies was associated with an increased rate of serious adverse events.

Indexed as

Tobacco Use Cessation DevicesAntidepressive Agents, Second-GenerationBenzazepinesBupropionHumansNicotinic AgonistsQuinoxalinesSmoking CessationAntidepressive Agents, Second-GenerationBenzazepinesBupropionNicotinic AgonistsQuinoxalines

Identifiers

PMID24399558

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.